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Background: Outcome heterogeneity, selective reporting, and 
choosing outcomes that do not reflect needs and priorities of 
stakeholders, limit the examination of health intervention effects, 
particularly in late phase trials. Core outcome sets (COS) are a 
proposed solution to these issues. A COS is an agreed-upon, 
standardised set of outcomes that should be measured and reported 
as a minimum in all trials in a specific area of health or healthcare. 
COS are intended to increase standardisation of outcome 
measurement and reporting to better enable comparisons between, 
and synthesis of findings of trials in a particular health area.  
Methods: This study will examine late phase trials, published between 
October 2019 and March 2020 (inclusive), in the following five medical 
journals: New England Journal of Medicine, Journal of the American 
Medical Association, Lancet, BMJ, and Annals of Internal Medicine. Trials 
will be examined to determine if they refer to a COS, and whether they 
use a COS. Trialists for each identified trial will subsequently be 
contacted to complete an online survey examining trialists’ awareness 
of, and decisions to search for and use a COS. 
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Discussion: This study will provide important information on uptake 
of COS by later phase trialists in major medical journals, and the views 
of these trialists on COS use in trials. These findings will inform 
approaches to increasing awareness and uptake of COS in future 
health trials.
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Introduction
Core outcome sets (COS) are standardised sets of agreed 
upon outcomes that should be measured and reported in all 
trials of a particular health area1. COS represent the minimum 
outcomes that should be measured and reported to facilitate 
standardisation and to improve the examination of intervention 
effectiveness1,2. Heterogeneity in outcomes across trials has 
been noted as a significant problem in terms of evidence syn-
theses because not all outcomes can be compared across trials3. 
Selective outcome reporting, or outcome reporting bias, which 
relates to inclusion of a subset of originally measured outcomes 
in the final publication is also problematic as it reduces research 
validity of trials and contributes to outcome heterogeneity4. 
Outcome heterogeneity and selective reporting limit transparent 
examinations of intervention effects and contribute to research 
waste5. In addition, outcomes included in trials do not always 
reflect those outcomes that are of importance to patients and other 
key stakeholders, such as healthcare professionals and policy 
makers6,7. COS represent an approach to minimising these 
problems by providing a minimum outcome set, that has been 
agreed by consensus by key stakeholders1.
Development and use of COS is supported by the COMET Ini-
tiative, and resources including a COS handbook1 and devel-
opment and reporting guidelines8–10 are available. The devel-
opment and use of COS in trials are increasing over time; the 
most recent update to a systematic review of COS development 
reported that over 300 COS studies have been published up to 
2019, and at least 200 are currently being developed11. Reviews 
of COS uptake indicate varying, though typically low, rates of 
COS use in trials12. Use of COS to inform outcome choice in 
systematic reviews has been reported as just 7% in a recent 2020 
review of 100 Cochrane reviews (Williamson et al. under review). 
Similarly, a recent examination of primary research applications 
to the National Institute for Health Research Health Technol-
ogy Assessment (NIHR HTA) reported that 19% of applicants 
referenced a COS in relation to outcome choice12. In this study, 
applicants reported that patient and public opinion, outcomes 
used in other studies, and recommendations from funders and/or 
professional bodies influenced outcome choice in funding 
applications12. Though research has been conducted on uptake 
of individual COS, and COS in specific health areas13, data on 
the use of COS in a general unselected cohort of published tri-
als is lacking. Examinations of trialists’ views and perceived 
barriers and facilitators to using COS in trials are similarly lack-
ing. This information is of importance to inform strategies to 
increase awareness and implementation of COS.
The aims of this study are to examine: (1) current practices of 
later phase trials published in top medical journals, in relation to 
the use of COS in choosing trial outcomes; and (2) views of trial 
authors on the use of COS in relation to choosing trial outcomes.
Methods
Search strategy
We will examine late phase trials published in the following 
journals: New England Journal of Medicine, Journal of the 
American Medical Association (JAMA), Lancet, BMJ, and Annals 
of Internal Medicine. Each journal website will be searched 
across a 6-month period, from October 2019 to March 2020. 
It is estimated that 115 trials, of various phases, have been pub-
lished in these journals during this timeframe and so this period 
has been chosen to ensure identification of a sufficient, yet prag-
matically manageable number of recent trials for review by the 
review team. In addition, this time frame ensures a sample of 
pre-COVID-19 trials (COVID-19 trials are being examined in a 
separate project in collaboration with https://covid-evidence.org).
Inclusion/exclusion criteria
Late phase trials will be eligible for inclusion. For this study, 
late phase trials are defined as studies examining effectiveness 
of an intervention (pharmacological or otherwise), typically in 
relation to standard care or another comparator. In pharmacologic 
trials, these are typically referred to as phase III or phase IV clini-
cal trials, though we are cognisant that this classification is not 
typically used in non-drug trials. In this study, late phase trials 
can include various trial designs (e.g. parallel, crossover, facto-
rial designs) and with any level of randomisation (e.g. individual 
and cluster levels). There are no restrictions based on sample size, 
topic/health area, or intervention type. Trials will not be included 
if they are: feasibility trials aiming to examine whether some 
aspect of the trial or intervention can be done14; pilot and explor-
atory trials preparing the conduct of the future trial, or part 
of the future trial, on a smaller scale14; follow-up studies; or 
secondary analyses of late phase trials, or phase 1 and phase 2 
studies.
Screening
Reviewer pairs will be established from the study team and will 
work together throughout the review process. Each reviewer 
pair will be allocated a random sample of trial publications from 
across the reviewed journals. As such, all articles published 
in the five journals noted from October 2019 to March 2020 will 
then be independently examined by two reviewers to determine 
whether they are late phase trials meeting eligibility criteria for 
inclusion in the review. Discrepancies between reviewers will 
be resolved by consensus discussion or by recourse to a third 
reviewer.
Data extraction and analysis
A standardised data extraction form will be used for all articles, 
with data extracted by one reviewer and verified by a second 
reviewer. Extracted data will include: author, date, title, funding 
information including location of funder, study aims, disease or 
health category (using the COMET categories), disease name, 
target population, type of intervention used. Data will also be 
extracted on whether a COS was mentioned and the reason for 
which it was mentioned (e.g. mentioned because it was used in 
trial, or mentioned to support a discussion point); whether a COS 
was used and if so, whether the full COS was used or whether 
only some COS outcomes were used. Details of the COS used 
will be extracted, including the individual outcomes used in trial 
that do not use the full COS. Whether the primary outcome of 
the trial was a COS, and if so which one, will also be extracted. 
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For trials not reporting use of a COS, the trial authors’ rationale 
and justification for the choice of outcomes used will be 
extracted from the published trial if reported.
In addition, for trials not reporting COS use, we will exam-
ine whether a COS existed that could have been used at the time 
of trial commencement to determine trial outcomes. This will 
be done by first searching for a published protocol or trial regis-
try entry (e.g. in ClinicalTrials.gov, ISRCTN registry) to iden-
tify an indication of when the trial started. As trials may begin 
prior to protocol publication/registration, this will be taken into 
account by extracting information on the start of trial recruit-
ment from either the registry entry or the trial publication. The 
COMET database will then be searched by disease and health 
categories to identify whether a potentially relevant COS could 
have been used for each trial based on the timing of trial com-
mencement and the timing of COS publication. Where a 
published protocol or trial registry entry cannot be identified 
to establish when the trial was being designed, the COMET 
database will be searched for a COS of relevant scope that 
had been published by 2017, such that it could potentially 
have informed choice of outcomes for the trial. We will check 
this assumption with the trialists (see below). A COS will be 
considered to be of relevant scope if it was developed for the 
same population (or a broader subset within which the trial 
population sits) and/or for the same intervention type (or a 
broader subset within which the trial intervention sits). Check-
ing the COMET database will be done by one reviewer with 
prior experience of identifying COS for specific populations and 
interventions, and will be verified by a second reviewer.
Survey of trialists
A survey will be sent to all corresponding authors of identi-
fied trials. When senior/corresponding authors cannot be con-
tacted via emails, another author from the author list (i.e. first or 
last author) will be approached. The survey will examine trial-
ists’ awareness of, and decisions to search for and use, a COS. 
An email will be sent to all trialists, including a link to the online 
survey, hosted on Google Forms® (see extended data15). One 
of four versions of the survey will be sent as follows: 1) where 
trial publications mentioned a COS and the full COS was used; 
2) where trial publications mentioned a COS and some but 
not all COS outcomes were used; 3) where trial publications do 
no mention a COS and we identified a potentially relevant COS 
that could have been used; and 4) where trial publications do no 
mention a COS and we did not identify a potentially relevant 
COS that could have been used. The surveys will ask about tri-
alists’ identification and use of a COS, or not; experiences and 
issues with COS use where a COS was used; and reasons for 
choice of outcomes where a COS was not used.
Analysis
Data collected from review of identified eligible trials and 
the survey of trialists will be analysed and presented descrip-
tively. The main outcomes of this study will be the numbers and 
percentage of trials using a COS and the numbers and percent-
age of trials that could have used a COS. Secondary outcomes are 
trialists’ awareness of, and decisions to search for and use, 
a COS. Open-ended survey questions will be analysed used 
content analysis. Findings will be presented narratively and in 
tabular format.
Ethical considerations and consent
Ethical approval is not necessary for examination of the pub-
lished trials but is required for, and will be obtained prior to 
commencement of, the trialist survey. All participants will 
receive an electronic information leaflet and, following reading 
this, will provide electronic consent prior to completing the online 
survey. While it is not anticipated that the survey will cause 
any distress, the researchers contact details will be provided at 
the end of the survey should participants wish to discuss any 
issues raised or be provided with further support contact details.
Dissemination
The findings of this study will be disseminated through the pub-
lication of peer-reviewed manuscripts. Additionally, findings 
will be presented at both national and international conferences.
Study status
This study has not yet commenced.
Discussion
Use of COS in trials is important to improve standardisa-
tion of outcomes, reduce bias and research waste, and improve 
examination and understanding of the effects of interventions 
in particular health areas. This study will provide information 
on the proportion of trialists in major medical journals who 
currently are, or are not, using COS. These findings will 
provide important insight into current uptake of COS in trials 
published in major medical journals. In addition, the study will 
provide information on trialists’ views and reasons for using, 
or not using, COS in trials. This is essential to better understand 
barriers and facilitators to COS uptake in medical trials.
Data availability
Underlying data
No data are associated with this article
Extended data
Open Science Framework: Uptake of core outcome sets by 
clinical trialists publishing in major medical journals. https:// 
doi.org/10.17605/OSF.IO/H4EKV15 
-    COS TMRP Survey.pdf (Four versions of survey to be 
used in study)
-    Uptake of COS by clinical trialists publishing in major 
medical journals.pdf (full study protocol document)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Christine Bond   
Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University 
of Aberdeen, Aberdeen, UK 
This is an interesting well written protocol for a study to explore whether researchers are using 
core outcome sets and if not why not. The method involves identifying and critically reviewing 
recently published papers in major journals followed by a survey of authors. The paper explains 
why this is an important topic and the value of researchers using core outcomes, especially for 
evidence synthesis. I have just a few comments for the authors to consider. 
 
My main concern is about greater clarity of what this review will add to the existing studies which 
have shown poor uptake of COS in Cochrane, previous trials and recently funded HTA applications 
(do these HTA application need more explanation for international audiences?). This review is 
looking at major impact journals but why is that important or different. Also I agree the selected 
journals are subjectively important and influential but is there an objective justification for their 
selection?  
 
 Are the authors suggesting Journal Editors should use their influence to encourage use of COS, in 
the same way as reporting guidelines are required?  
 
In many ways the triallists’ views are the most interesting aspect of the paper as a way of 
understanding what needs to be done in the future to promote use of COS. Building on that, could 
behavioural theory be used to inform the questions asked and allow identification of appropriate 
behaviour change interventions? 
  
Minor points
Is there a justification for the sample size of estimated 115 papers? This relates both to the 




Is ‘pharmacologic trials’ a normal label? Often referred to more as investigational products 2. 
HRB Open Research
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or drug trials. 
 
Under items to be extracted some e.g. disease name will not necessarily always be relevant. 
 
3. 
For trials not reporting COS or part of COS is there a field for specifying the outcome that 
was actually used as well as any justification, for that decision? 
 
4. 
First column page 4 has a longish paragraph on identifying if a relevant COS existed at the 
time of the trial. There is reference to time of designing the trial as being the base line. I am 
not sure how easy the date of the initial design would be to identify but one option might be 
to look at a relevant date of any grant application if the study had been externally funded. 
 
5. 
In the same paragraph maybe add initials of the reviewer with prior experience and the 
second reviewer as presume they are members of the authorship team. 
 
6. 
Will any inferential statistics be conducted on the survey results? 
 
7. 




Who is funding this work?9. 
 
Is the rationale for, and objectives of, the study clearly described?
Partly
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Mixed methods health services researcher who has been part of a team 
developing a COS.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
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